Review of the BAHRS Annual Conference 2024: Managing the Hair Loss Patient Holistically May 11, 2024, Olympia, London

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A 24-year-old with early hair loss is managing it with finasteride, minoxidil, and dutasteride, and is considering using a hair system for more styling options while maintaining transparency. They emphasize confidence and self-expression over hair, viewing it as an amplifier rather than a foundation.

A 21-year-old with accelerated hair loss due to stress and weight loss is using minoxidil, finasteride, and microneedling to combat balding, despite experiencing a significant initial hair shed. They are committed to continuing treatment for at least three months and are considering switching to topical finasteride if necessary.